These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

132 related items for PubMed ID: 7827170

  • 1. Antisense oligodeoxynucleotides.
    Stein CA, Narayanan R.
    Curr Opin Oncol; 1994 Nov; 6(6):587-94. PubMed ID: 7827170
    [Abstract] [Full Text] [Related]

  • 2. The therapeutic potential of antisense oligonucleotides.
    Sharma HW, Narayanan R.
    Bioessays; 1995 Dec; 17(12):1055-63. PubMed ID: 8634067
    [Abstract] [Full Text] [Related]

  • 3. Antisense-mediated inhibition of BCL2 protooncogene expression and leukemic cell growth and survival: comparisons of phosphodiester and phosphorothioate oligodeoxynucleotides.
    Reed JC, Stein C, Subasinghe C, Haldar S, Croce CM, Yum S, Cohen J.
    Cancer Res; 1990 Oct 15; 50(20):6565-70. PubMed ID: 2208117
    [Abstract] [Full Text] [Related]

  • 4. The influence of target protein half-life on the effectiveness of antisense oligonucleotide analog-mediated biologic responses.
    Spiller DG, Giles RV, Broughton CM, Grzybowski J, Ruddell CJ, Tidd DM, Clark RE.
    Antisense Nucleic Acid Drug Dev; 1998 Aug 15; 8(4):281-93. PubMed ID: 9743466
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. In vivo treatment of human leukemia in a scid mouse model with c-myb antisense oligodeoxynucleotides.
    Ratajczak MZ, Kant JA, Luger SM, Hijiya N, Zhang J, Zon G, Gewirtz AM.
    Proc Natl Acad Sci U S A; 1992 Dec 15; 89(24):11823-7. PubMed ID: 1281545
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Controversies in the cellular pharmacology of oligodeoxynucleotides.
    Stein CA.
    Ciba Found Symp; 1997 Dec 15; 209():79-89; discussion 89-93. PubMed ID: 9383570
    [Abstract] [Full Text] [Related]

  • 10. Does antisense make sense in dermatology?
    van Erp PE, Wingens M.
    Acta Derm Venereol; 2001 Dec 15; 81(6):385-91. PubMed ID: 11859937
    [Abstract] [Full Text] [Related]

  • 11. Suppression of Philadelphia1 leukemia cell growth in mice by BCR-ABL antisense oligodeoxynucleotide.
    Skorski T, Nieborowska-Skorska M, Nicolaides NC, Szczylik C, Iversen P, Iozzo RV, Zon G, Calabretta B.
    Proc Natl Acad Sci U S A; 1994 May 10; 91(10):4504-8. PubMed ID: 8183938
    [Abstract] [Full Text] [Related]

  • 12. Antisense therapy.
    Narayanan R, Akhtar S.
    Curr Opin Oncol; 1996 Nov 10; 8(6):509-15. PubMed ID: 8971471
    [Abstract] [Full Text] [Related]

  • 13. Selective anti-gene therapy for cancer: principles and prospects.
    Cohen JS.
    Tohoku J Exp Med; 1992 Oct 10; 168(2):351-9. PubMed ID: 1306320
    [Abstract] [Full Text] [Related]

  • 14. Urokinase antisense oligodeoxynucleotides as a novel therapeutic agent for malignant glioma: in vitro and in vivo studies of uptake, effects and toxicity.
    Engelhard H, Narang C, Homer R, Duncan H.
    Biochem Biophys Res Commun; 1996 Oct 14; 227(2):400-5. PubMed ID: 8878527
    [Abstract] [Full Text] [Related]

  • 15. Effect of bcr-abl oligodeoxynucleotides on the clonogenic growth of chronic myelogenous leukaemia cells.
    de Fabritiis P, Skorski T, De Propris MS, Paggi MG, Nieborowska-Skorska M, Lisci A, Buffolino S, Campbell K, Geiser T, Calabretta B.
    Leukemia; 1997 Jun 14; 11(6):811-9. PubMed ID: 9177433
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.